Otezla for plaque psoriasis and psoriatic arthritis

Apremilast (Otezla), a new oral PDE4 inhibitor, is licensed for the treatment of plaque psoriasis and psoriatic arthritis. Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Dr Giles Dunnill discusses its place in therapy.

Otezla for plaque psoriasis and psoriatic arthritis

Add yours ↓
Web design and marketing agency Leamington Spa